Burning Rock Biotech Limited

Strategic NGS platform supplier (DNBSEQ sequencing technology); Burning Rock's OncoScreen Plus CDx powered by MGI's DNBSEQ platform; Japan regulatory approval achieved jointly

GeneMind Biosciences Co., Ltd.

Alternative sequencing platform supplier (GenoLab M sequencer); Burning Rock's assays optimized for GeneMind platforms

Thermo Fisher Scientific, Inc.

NYSE:TMO

Supplier of NGS platforms (Ion Torrent), reagents, consumables, and lab equipment; used in some Burning Rock workflows

Element Biosciences, Inc.

Emerging sequencing platform supplier (AVITI benchtop sequencer); Burning Rock assays compatible with Element platforms

하류

생산물을 소화하는 고객, 유통사, OEM 및 판매 채널.

하류

Bayer AG

Merck KGaA

Boehringer Ingelheim

Abbisko Therapeutics (Abbisko Cayman Ltd)

Shanghai Zhongshan Hospital

AstraZeneca PLC

NASDAQ:AZN

Strategic CDx partnership in China for breast and prostate cancer therapies (Capivasertib CDx approved in Japan 2025); major pharma R&D services revenue contributor

Bayer AG

ETR:BAYN

CDx collaboration (May 2024) to jointly develop NGS-based companion diagnostics for Bayer's precision oncology portfolio in China

Merck KGaA

ETR:MRK

CDx collaboration (Nov 2021) to develop liquid-biopsy based CDx for tepotinib (MET inhibitor) using OncoCompass Target panel

Boehringer Ingelheim

Master Service Agreement (Oct 2023) for CDx development focused on brigimadlin (MDM2-p53 antagonist) and other oncology assets in China

CStone Pharmaceuticals

HKEX:2616

Strategic partnership (June 2020) to co-develop companion diagnostics for pralsetinib in China

대체 기업

분석에서 대표로 사용하는 상장 비교 기업 및 모니터링 종목.

대체 기업

BGI Genomics Co., Ltd.

Illumina, Inc.

BGI Genomics Co., Ltd.

SZSE:300676

Largest Chinese genomics company; parent of MGI Tech (sequencing platform supplier to Burning Rock). Shares China NGS market exposure and regulatory environment.

Guardant Health, Inc.

NASDAQ:GH

US-based precision oncology NGS testing company with similar business model (liquid biopsy, CDx partnerships). Proxy for NGS-based oncology diagnostics valuation and market dynamics.

Illumina, Inc.

NASDAQ:ILMN

Dominant upstream NGS platform supplier to Burning Rock. Illumina's China exposure and instrument sales directly affect Burning Rock's operational capabilities.

지역

공급망을 왜곡할 수 있는 지역별 노출.

지역

China

United States

National Cancer Center of China

94+ Partner Hospitals (China network)

AstraZeneca PLC

Illumina, Inc.

Burning Rock US Lab (Irvine, CA)

IMPACT Therapeutics, Inc.

China

Operational & Regulatory Dependency

National Cancer Center of ChinaClinical study partner; dependent on China's healthcare regulatory environment

94+ Partner Hospitals (China network)Primary testing service channel; subject to China healthcare policy and pricing reforms

AstraZeneca PLCNASDAQ:AZNCDx collaboration for China market; China healthcare regulatory changes impact

United States

US-China Trade & Sanctions Risk

Illumina, Inc.NASDAQ:ILMNPrimary NGS instrument supplier; subject to US export controls to China

Burning Rock US Lab (Irvine, CA)CLIA/CAP certified US laboratory supporting global clinical trials; subject to US regulations

IMPACT Therapeutics, Inc.HKEX:7630Global CDx partnership; US clinical trial activities subject to FDA oversight

집중도

공급망을 왜곡할 수 있는 고객, 공급업체 또는 파트너 집중 노출.

Equipment

Critical

Heavy reliance on Illumina as primary sequencing platform supplier. Illumina holds dominant market share in NGS instruments. Any disruption in Illumina supply, pricing changes, or export restrictions could materially impact operations.

Foundry

High

Illumina/MGI sequencer availability subject to US-China trade tensions. Chinese suppliers (MGI, GeneMind) provide alternative but may face IP and technology gap challenges.

Customer

Medium

Revenue concentration on a few large pharma partners for CDx services. Pharma R&D spend fluctuations or partnership terminations could impact service revenue growth.

Other

Medium

China NMPA regulatory concentration - most revenue and IVD kit approvals are China-centric. Limited geographic diversification of regulatory approvals.

매출 구성

대상 기업의 매출 구성이 공급망 영향력과 의존도로 이어지는 방식.

Product Revenue (IVD Kits & NGS Reagent Kits)

41.4%

$0.0B

Drives demand for NGS sequencing instruments, reagents, consumables, and raw materials from upstream suppliers like Illumina and MGI Tech. NMPA-approved kits require specific platform compatibility.

Service Revenue (Central Lab Testing, In-Hospital Testing & Pharma R&D Services)

58.6%

$0.0B

Central lab and in-hospital testing drive demand for sequencing instruments, consumables (flow cells, reagents, DNA extraction kits), and bioinformatics infrastructure. Pharma R&D services (CDx) depend on pharma customer relationships and clinical trial activity.

회사 소개개인정보 처리방침서비스 약관면책 조항종목 디렉터리ETF지수13F 보유 종목목표주가무료 도구기술 지도Slack 참여하기

Plutux는 투자자문업자가 아닙니다. 시장 데이터와 AI가 생성한 분석은 정보 제공 및 교육 목적일 뿐 투자 자문이 아닙니다. 면책 조항

Burning Rock Biotech Limited

BNR 공급망

상류

Illumina, Inc.

MGI Tech Co., Ltd.

GeneMind Biosciences Co., Ltd.

Thermo Fisher Scientific, Inc.

Element Biosciences, Inc.

BGI Group / BGI Genomics Co., Ltd.

하류

AstraZeneca PLC

Bayer AG

Merck KGaA

Boehringer Ingelheim

CStone Pharmaceuticals

Abbisko Therapeutics (Abbisko Cayman Ltd)

IMPACT Therapeutics, Inc.

Shanghai Zhongshan Hospital

View More

대체 기업

BGI Genomics Co., Ltd.

Guardant Health, Inc.

Illumina, Inc.

지역

China

United States

BNR 공급망

상류

Illumina, Inc.

MGI Tech Co., Ltd.

GeneMind Biosciences Co., Ltd.

Thermo Fisher Scientific, Inc.

Element Biosciences, Inc.

BGI Group / BGI Genomics Co., Ltd.

하류

AstraZeneca PLC

Bayer AG

Merck KGaA

Boehringer Ingelheim

CStone Pharmaceuticals

Abbisko Therapeutics (Abbisko Cayman Ltd)

IMPACT Therapeutics, Inc.

Shanghai Zhongshan Hospital

View More

대체 기업

BGI Genomics Co., Ltd.

Guardant Health, Inc.

Illumina, Inc.

지역

China

United States